Rare Disease Framework Public Meeting: Recording Now Available

The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), hosted the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases. As outlined in a new white paper, the Initiative will develop an optimized, fit-for-purpose framework that reflects the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small patient populations.

Jon Hagstrom, A1F Board of Directors Chair comments at timestamp 1:10:40

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.